Silexion Therapeutics's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Silexion Therapeutics (SLXN) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Silexion Therapeutics's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Silexion Therapeutics Corp | - | - | - | No |
| High-Confidence Competitors (13) | ||||
| Similar-Size Competitors (8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
SLXN Stock Performance relative to its Competitors
SLXN Stock Performance relative to High-Confidence Competitors
SLXN Stock Performance relative to Similar-Size Competitors
Silexion Therapeutics's Comment on Competition and Industry Peers
Silexion Therapeutics's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Astellas | Named by the company | 85% |
| BridgeBio Oncology | Named by the company | 85% |
| GenFleet | Named by the company | 85% |
| Merck/Moderna | Named by the company | 85% |
| Usynova | Named by the company | 85% |
| Adlai Nortye | Named by the company | 85% |
| BioNTech | Named by the company | 85% |
| Chugai (Roche) | Named by the company | 85% |
| Lilly | Named by the company | 85% |
| Revolution Medicines | Named by the company | 85% |
| AstraZeneca | Named by the company | 85% |
| Bristol-Myers Squibb | Named by the company | 85% |
| Gilead | Named by the company | 85% |
| Moderna | Named by the company | 85% |
| Amgen | Named by the company | 85% |
| Boehringer | Named by the company | 85% |
| Erasca (ex Joyo) | Named by the company | 85% |
| Merck | Named by the company | 85% |
| Roche | Named by the company | 85% |
| BeOne | Named by the company | 85% |
| Chengdu Hyperway | Named by the company | 85% |
| Jacobio | Named by the company | 85% |
| Pfizer | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Silexion Therapeutics's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.